NCI-2022-00633

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors

This Phase 1a/1b study is designed to evaluate the safety and tolerability of a drug called STK-012 on its own and in combination with pembrolizumab, an immunotherapy medicine, for selected advanced solid tumors. The study aims to assess the safety profile of STK-012 when administered alone and in combination with pembrolizumab. Researchers will also evaluate the effectiveness of these treatments in shrinking tumors and improving patient outcomes.

immunotherapy medicine: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05098132

Clinical Trial Site: Columbia

To see all available clinical trials click here.